Number of suitable clients: CDEC talked over the uncertainty in the number of patients with reasonably intense to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be classified as having gentle